trial_id	phase	recruitmentstatus	actualstartdate	short_title	drug_list	drug_classes	secondaryid	studytitle	healthcondition	healthconditioncode	ext_weblink
NCT05038631	Phase 4	Available	September 9, 2021	Managed Access Program to Provide Access to Ribociclib, for Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options and Candidate for Therapy With a CDK Inhibitor	Ribociclib	CDK4/6_inhibitor	CLEE011A2408	Managed Access Program to Provide Access to Ribociclib, for Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options and Candidate for Therapy With a CDK Inhibitor	Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options and Candidate for Therapy With a CDK Inhibitor	DOID:162	https://clinicaltrials.gov/ct2/show/NCT05038631
NCT04853602	Phase 4	Available	April 21, 2021	IFx-Hu2.0 Expanded Access Program	Ifosfamide	alkylating_agent	IFx-Hu2.0 Expanded Access	IFx-Hu2.0 Expanded Access Program	Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma	DOID:3151; DOID:3965; DOID:8923	https://clinicaltrials.gov/ct2/show/NCT04853602
NCT04830202	Phase 4	Available	April 5, 2021	Expanded Access to Telisotuzumab Vedotin	Telisotuzumab Vedotin	anti-c-Met_antibody-drug_conjugate	C20-503	Expanded Access to Telisotuzumab Vedotin	Non-Small Cell Lung Cancer (NSCLC)	DOID:3908	https://clinicaltrials.gov/ct2/show/NCT04830202
NCT04829422	Phase 4	Available	April 2, 2021	Early Access Program of Lazertinib in Republic of Korea	Lazertinib	EGFR_inhibitor,third_generation	LASER-EAP	Early Access Program of Lazertinib in Republic of Korea	Lung Cancer	DOID:1324	https://clinicaltrials.gov/ct2/show/NCT04829422
NCT04825652	Phase 4	Available	April 1, 2021	177Lu-PSMA-617 Managed Access Program for mCRPC Patients	Lutetium-177-PSMA-617	177Lu-PSMA-radioconjugate	CAAA617A12001M	177Lu-PSMA-617 Managed Access Program for mCRPC Patients	Metastatic Castration-resistant Prostate Cancer (mCRPC)	DOID:10283	https://clinicaltrials.gov/ct2/show/NCT04825652
NCT04814732	Phase 4	Available	March 24, 2021	Expanded Access Program of Surufatinib	Surufatinib	CSF1R_inhibitor; FGFR1_inhibitor; VEGFR_inhibitor	2020-012-GLOB3	Expanded Access Program of Surufatinib	Neuroendocrine Tumors	DOID:169	https://clinicaltrials.gov/ct2/show/NCT04814732
NCT04777734	Phase 4	Available	March 2, 2021	Efgartigimod Expanded Access for Generalized Myasthenia Gravis	Leucovorin	folinic_acid	ARGX-113-EAP-2101	Efgartigimod Expanded Access for Generalized Myasthenia Gravis	Generalized Myasthenia Gravis	DOID:437	https://clinicaltrials.gov/ct2/show/NCT04777734
NCT04757259	Phase 4	Available	February 17, 2021	Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib	Cerdulatinib	Syk_inhibitor	20-605	Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib	Non-hodgkin's Lymphoma; Relapsed/Refractory Chronic Lymphocytic Leukemia	DOID:1040; DOID:8567	https://clinicaltrials.gov/ct2/show/NCT04757259
NCT04741789	Phase 4	Available	February 5, 2021	Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)	Capmatinib	MET_inhibitor,type_1	CINC280A02001M	Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)	Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer; Non-Small-Cell Lung Carcinoma; Nonsmall Cell Lung Cancer	DOID:1324; DOID:305; DOID:3908	https://clinicaltrials.gov/ct2/show/NCT04741789
NCT04678466	Phase 4	Available	December 22, 2020	Flotetuzumab Expanded Access Program	FLOT	Fluorouracil + Oxaliplatin + Docetaxel	MGD006-EA	Flotetuzumab Expanded Access Program	AML; AML, Adult Recurrent; Acute Myeloid Leukemia	DOID:9119	https://clinicaltrials.gov/ct2/show/NCT04678466
NCT04566393	Phase 4	Available	September 28, 2020	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	Ulixertinib	ERK_inhibitor	ULI-EAP-100	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	BRAF Gene Mutation; Bladder Cancer; Cholangiocarcinoma; Colorectal Cancer; ERK Mutation; Esophageal Cancer; Gastric Cancer; Glioblastoma; HRAS Gene Mutation; Head and Neck Cancer; Hepatocellular Carcinoma; KRAS Activating Mutation; MAPK Gene Mutation; MEK Mutation; Melanoma; NRAS Gene Mutation; Non Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Small Bowel Cancer; Thyroid Cancer	DOID:0050861; DOID:10534; DOID:11054; DOID:11934; DOID:162; DOID:1781; DOID:1793; DOID:1909; DOID:2394; DOID:3068; DOID:3908; DOID:4947; DOID:5041; DOID:684	https://clinicaltrials.gov/ct2/show/NCT04566393
NCT04559555	Phase 4	Available	September 23, 2020	MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Nilotinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFR_inhibitor	CAMN107A2412	MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Acute Lymphoblastic Leukemia (ALL)	POTTR:1004	https://clinicaltrials.gov/ct2/show/NCT04559555
NCT04544202	Phase 4	Available	September 10, 2020	Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor	CDRB436F2001CM	Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection	Adjuvant; Melanoma	DOID:1909	https://clinicaltrials.gov/ct2/show/NCT04544202
NCT04518644	Phase 4	Available	August 19, 2020	Nilotininb, for Patients With CML-CP, CML-AP, or CML-BC	Nilotinib	BCR-ABL1_inhibitor,second_generation; KIT_inhibitor; PDGFR_inhibitor	CAMN107A2411	Nilotininb, for Patients With CML-CP, CML-AP, or CML-BC	Chronic Myelogenous Leukemia (CML)	POTTR:1003	https://clinicaltrials.gov/ct2/show/NCT04518644
NCT04507503	Phase 4	Available	August 11, 2020	Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements	Futibatinib	pan-FGFR_inhibitor,irreversible	TAS-120-401	Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements	Advanced Cholangiocarcinoma	DOID:4947	https://clinicaltrials.gov/ct2/show/NCT04507503
NCT04507919	Phase 4	Available	August 11, 2020	Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer	Dabrafenib	BRAF_V600_inhibitor	CTMT212X2002I	Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer	Small Cell Lung Carcinoma	DOID:3905	https://clinicaltrials.gov/ct2/show/NCT04507919
NCT04489433	Phase 4	Available	July 28, 2020	Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAFmutation-positive Metastatic Melanoma	Dabrafenib; Trametinib	BRAF_V600_inhibitor; MEK_inhibitor	CDRB436B2005CM	Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAFmutation-positive Metastatic Melanoma	Melanoma	DOID:1909	https://clinicaltrials.gov/ct2/show/NCT04489433
NCT04473040	Phase 4	Available	July 16, 2020	Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer	Alpelisib	PI3K_alpha_inhibitor	CBYL719C2001M	Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer	HR+, HER2-, Advanced Breast Cancer	DOID:1612	https://clinicaltrials.gov/ct2/show/NCT04473040
NCT04360005	Phase 4	Available	April 24, 2020	Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase	Asciminib	BCR-ABL1_inhibitor	CABL001A02401M	Managed Access Program (MAP)* to Provide Access to Asciminib for Patients With CML in Chronic Phase	Chronic Myeloid Leukemia	DOID:8552	https://clinicaltrials.gov/ct2/show/NCT04360005
NCT04100694	Phase 4	Available	September 24, 2019	Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor	MCLA-128	bispecific_ERBB2/ERBB3_monoclonal_antibody	MCLA-128-CL99; MCLA-128-CL98	Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor	Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Cancer; NRG1; NRG1 Fusion; Non Small Cell Lung Cancer; Pancreatic Cancer; Prostate Cancer; Renal Cell Carcinoma; Solid Tumor, Unspecified, Adult; Unknown Primary Tumors	DOID:0050861; DOID:10283; DOID:11934; DOID:1612; DOID:162; DOID:1793; DOID:3908; DOID:4450; DOID:4947; POTTR:0001	https://clinicaltrials.gov/ct2/show/NCT04100694
NCT03994627	Phase 4	Available	June 21, 2019	Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	Olaratumab	anti-PDGFRA_monoclonal_antibody	17468	Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	Soft Tissue Sarcoma	DOID:1115	https://clinicaltrials.gov/ct2/show/NCT03994627
NCT03906331	Phase 4	Available	April 8, 2019	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Selpercatinib	RET_inhibitor	17494	Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation	Breast Cancer; Colon Cancer; Medullary Thyroid Cancer; Non Small Cell Lung Cancer; Other Solid Tumors With Evidence of Activating RET Alteration; Pancreatic Cancer; Papillary Thyroid Cancer	DOID:1612; DOID:1781; DOID:1793; DOID:219; DOID:3908; DOID:3973; POTTR:0001	https://clinicaltrials.gov/ct2/show/NCT03906331
NCT03874455	Phase 4	Available	March 14, 2019	Tazemetostat Expanded Access Program for Adults With Solid Tumors	Tazemetostat	EZH2_inhibitor	EZH-701	Tazemetostat Expanded Access Program for Adults With Solid Tumors	Epithelioid Sarcoma (Ex-US Only); Poorly Differentiated Chordoma; Sinonasal Carcinoma; Small Cell Carcinoma of the Ovary Hypercalcemic Type; Spindle Cell Sarcoma; Thoracic Sarcoma	DOID:0050685; DOID:1115; DOID:305; DOID:3302; DOID:4235; DOID:6193	https://clinicaltrials.gov/ct2/show/NCT03874455
NCT03763604	Phase 4	Available	December 4, 2018	Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Abemaciclib	CDK4/6_inhibitor	17088	Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer	Metastatic Breast Cancer	DOID:1612	https://clinicaltrials.gov/ct2/show/NCT03763604
NCT03601442	Phase 4	Available	July 26, 2018	CTL019 Out of Specification MAP for ALL or DLBCL Patients	Tisagenlecleucel	CD19-directed_CAR_T_cell	CCTL019B2003I	CTL019 Out of Specification MAP for ALL or DLBCL Patients	Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-cell Lymphoma (DLBCL)	DOID:0050745; POTTR:1004	https://clinicaltrials.gov/ct2/show/NCT03601442
NCT03592576	Phase 4	Available	July 19, 2018	Expanded Access to Navitoclax	Navitoclax; Venetoclax	BCL2_inhibitor	C19-199	Expanded Access to Navitoclax	Acute Lymphocytic Leukemia (ALL); Lymphoblastic Lymphoma; Myelofibrosis	DOID:0060058; DOID:4971; DOID:9952	https://clinicaltrials.gov/ct2/show/NCT03592576
NCT03414489	Phase 4	Available	January 30, 2018	Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)	Opaganib	sphingosine_kinase-2_inhibitor	ABC-108-EA	Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)	Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Perihilar	DOID:4947	https://clinicaltrials.gov/ct2/show/NCT03414489
NCT03138629	Phase 4	Available	May 3, 2017	Expanded Access to VAL-083	VAL-083	alkylating_agent	DLM-17-002	Expanded Access to VAL-083	Cancer	DOID:162	https://clinicaltrials.gov/ct2/show/NCT03138629
NCT03123029	Phase 4	Available	April 21, 2017	Expanded Access to Venetoclax	Venetoclax	BCL2_inhibitor	C16-431	Expanded Access to Venetoclax	Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Amyloidosis; Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma; Non-Hodgkin's Lymphoma; Plasma Cell Leukemia	DOID:1040; DOID:1240; DOID:8567; DOID:9119; DOID:9120; DOID:9538; POTTR:1004	https://clinicaltrials.gov/ct2/show/NCT03123029
NCT03123211	Phase 4	Available	April 21, 2017	Expanded Access to Veliparib	Veliparib	PARP_inhibitor	C16-468	Expanded Access to Veliparib	High Grade Serous Ovarian Cancer; Patients Requiring Veliparib Suspension Formulation; Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound; Triple Negative Breast Cancer (TNBC)	DOID:1612; DOID:2394; POTTR:0001	https://clinicaltrials.gov/ct2/show/NCT03123211
